Vascular endothelial growth factor: Regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy

Oncologist

Volumn 7, Issue SUPPL. 3, 2002, Pages 4-11

  Conti, Claudio J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Clinical trials; Ras oncogene; Squamous skin carcinoma; Therapy related cancer; Tumor angiogenesis; Vascular endothelial growth factor

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 7,12 DIMETHYLBENZ[A]ANTHRACENE; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANGIOZYME; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYTOSTATIC AGENT; DOCETAXEL; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GEMCITABINE; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; PACLITAXEL; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN P16; PROTEIN P53; SEMAXANIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VATALANIB; ZK 22584; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; RAS PROTEIN; SIGNAL PEPTIDE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; CARCINOGENESIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HYPOXIA; MELANOMA; MOUSE; NONHUMAN; ONCOGENE NEU; ONCOGENE RAS; ONCOGENE SRC; PRIORITY JOURNAL; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; ANIMAL; CHEMICALLY INDUCED DISORDER; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; SKIN TUMOR;

ANIMALS; CARCINOMA, SQUAMOUS CELL; ENDOTHELIAL GROWTH FACTORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MICE; NEOVASCULARIZATION, PATHOLOGIC; RAS PROTEINS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036054742     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-suppl_3-4     Document Type: Conference Paper

References (97)

1. Tumor angiogenesis: Therapeutic implications
2. Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins
3. FGF and VEGF function in angiogenesis: Signalling pathways, biological responses and therapeutic inhibition
4. Vessel co-option, regression, and growth in tumors mediated by angiopoietins and VEGF
5. Vasculogenesis
6. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
7. Mechanisms of angiogenesis
8. Oncogenes and angiogenesis: Signaling three-dimensional tumor growth
9. Hypoxia modulated gene expression: Angiogenesis, metastasis and therapeutic exploitation
10. The biology of vascular endothelial growth factor
11. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
12. Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor
13. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells
14. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
15. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells
16. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
17. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an antivascular endothelial growth factor/vascular permeability factor antibody
18. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
19. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
20. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing
21. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing
22. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels
23. Functions of the von Hippel-Lindau tumour suppressor protein
24. Cox-2, iNOS and p53 as play-makers of tumor angiogenesis
25. Restoration of wildtype p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas
26. Oncogenes as inducers of tumor angiogenesis
27. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
28. Multistage carcinogenesis in mouse skin
29. Cutaneous carcinogenesis: Natural and experimental
30. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis
31. Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression
32. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
33. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells
34. Altered expression of the epidermal growth factor receptor and transforming growth factor-alpha during multistage skin carcinogenesis in SENCAR mice
35. Targeted disruption of the epidermal growth factor receptor impairs growth of squamous papillomas expressing the v-ras(Ha) oncogene but does not block in vitro keratinocyte responses to oncogenic ras
36. The epidermal growth factor receptor is required to maintain the proliferative population in the basal compartment of epidermal tumors
37. A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis
38. Oncogenes and tumor angiogenesis: Differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts
39. Differentiation of endothelium
40. Angiogenesis is an early event in the development of chemically induced skin tumors
41. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development
42. Expression of type VI collagen mRNA during wound healing
43. Entactin immunoreactivity in immature and adult rat brain
44. Thy-1, a novel marker for angiogenesis upregulated by inflammatory cytokines
45. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma
46. Genes expressed in human tumor endothelium
47. Cell surface tumor endothelial markers are conserved in mice and humans
48. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation
49. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells
50. Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration
51. Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion
52. Angiopoietin-1 induces sprouting angiogenesis in vitro
53. Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2
54. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
55. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
56. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188
57. VEGF: An update on biological and therapeutic aspects
58. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
59. Clinical trials referral resource: Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab
60. Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen
61. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
62. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy
63. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice
64. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2
65. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ
66. Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes
67. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma
68. Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2
69. Ribozyme pharmacokinetic screening for predicting pharmacodynamic dosing regimens
70. Angiozyme: A novel angiogenesis inhibitor
71. Angiozyme pharmacokinetic and safety results: A phase I/II study in patients with refractory solid tumors
72. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
73. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
74. Clinical trials referral resource. Current clinical trials administering the antiangiogenesis agent SU5416
75. A phase I and pharmacokinetic study of single oral administration of SU5416 in patients with advanced solid tumors
76. A phase II study with SU5416 in patients with C-Kit positive AML
77. SU5416 in malignant mesothelioma: A University of Chicago phase II consortium study
78. Phase II study of the anti-angiogenic Flk-1 tyrosine kinase inhibitor SU5416 in melanoma: Initial results
79. SU5416 in advanced colorectal cancer (CRC): A University of Chicago phase II consortium study
80. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
81. Phase I experience with SU6668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies
82. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
83. Tyrosine kinase inhibitors: From rational design to clinical trials
84. Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging, of 2 phase 1 studies of the VEGF Inhibitor PTK787/ZK222584 in patients with liver metastases from colorectal cancer
85. A phase-1 dose-escalating and pharmacokinetic (PK) study of the VEGF-receptor-inhibitor PTK787/ZK222584 (PTK/ZK) in patients with liver metastasis of advanced cancer
86. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy
87. Inhibition of VEGF signal transduction. Identification of ZD4190
88. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
89. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
90. Angiostatin binds ATP synthase on the surface of human endothelial cells
91. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD
92. Multiple forms of angiostatin induce apoptosis in endothelial cells
93. Inhibitory effect of full-length human endostatin on in vitro angiogenesis
94. Endostatin induces endothelial cell apoptosis
95. 'Accidental' anti-angiogenic drugs. Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples
96. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes
97. Redefining the target: Chemotherapeutics as antiangiogenics